Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.500
-0.110 (-3.05%)
At close: Jun 27, 2025, 4:00 PM
3.470
-0.030 (-0.86%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -95.12% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.12%
P/S Ratio
14,193.72
Revenue / Employee
$339
Employees
59
Market Cap
283.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALT News
- 6 hours ago - Altimmune's Fatty Liver Candidate Faces Differentiation Doubts - Benzinga
- 1 day ago - Altimmune: Deciphering The MASH Crash (Rating Upgrade) - Seeking Alpha
- 1 day ago - Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide - Seeking Alpha
- 1 day ago - Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 1 day ago - Altimmune's weight-loss drug meets main goal in fatty liver disease trial - Reuters
- 1 day ago - Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH - GlobeNewsWire
- 2 days ago - Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 - GlobeNewsWire
- 14 days ago - Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - GlobeNewsWire